FDA’s Autologous Cell Therapy Stance Needs Clarification, CTI Says
Executive Summary
FDA needs to address the "unique aspects" of property rights involved in the medical use of autologous cell therapy, Cancer Therapeutics, Inc. told the agency in an exchange of letters regarding the regulatory status of CTI's research programs